SEARCH

SEARCH BY CITATION

References

  • Bateman R. J., Xiong C., Benzinger T. L. et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795804.
  • Beckett T. L., Webb R. L., Niedowicz D. M., Holler C. J., Matveev S., Baig I., LeVine H., 3rd, Keller J. N. and Murphy M. P. (2012) Postmortem Pittsburgh compound B (PiB) binding increases with Alzheimer's disease progression. J. Alzheimers Dis. 32, 128137.
  • Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248254.
  • Cairns N. J., Ikonomovic M. D., Benzinger T. et al. (2009) Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease. Arch. Neurol. 66, 15571562.
  • Chan W., Fornwald J., Brawner M. and Wetzel R. (1996) Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide Abeta. Biochemistry 35, 71237130.
  • Chan R. B., Oliveira T. G., Cortes E. P., Honig L. S., Duff K. E., Small S. A., Wenk M. R., Shui G. and Di Paolo G. (2012) Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287, 26782688.
  • Cho H. S., Hyman B. T., Greenberg S. M. and Rebeck G. W. (2001) Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J. Neuropathol. Exp. Neurol. 60, 342349.
  • Cohen A. D., Rabinovici G. D., Mathis C. A., Jagust W. J., Klunk W. E. and Ikonomovic M. D. (2012) Using Pittsburgh compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv. Pharmacol. 64, 2781.
  • Dubois B., Feldman H. H., Jacova C. et al. (2010) Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 11181127.
  • Fast R., Rodell A., Gjedde A., Mouridsen K., Alstrup A. K., Bjarkam C. R., West M. J., Berendt M. and Moller A. (2013) PiB fails to map amyloid deposits in cerebral cortex of aged dogs with canine cognitive dysfunction. Front. Aging Neurosci. 5, 99.
  • Folch J., Lees M. and Sloane Stanley G. H. (1957) A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497509.
  • Forsell C., Bjork B. F., Lilius L., Axelman K., Fabre S. F., Fratiglioni L., Winblad B. and Graff C. (2010) Genetic association to the amyloid plaque associated protein gene COL25A1 in Alzheimer's disease. Neurobiol. Aging 31, 409415.
  • Gellermann G. P., Appel T. R., Tannert A. et al. (2005) Raft lipids as common components of human extracellular amyloid fibrils. Proc. Natl Acad. Sci. USA 102, 62976302.
  • Gellermann G. P., Appel T. R., Davies P. and Diekmann S. (2006) Paired helical filaments contain small amounts of cholesterol, phosphatidylcholine and sphingolipids. Biol. Chem. 387, 12671274.
  • Handen B. L., Cohen A. D., Channamalappa U., Bulova P., Cannon S. A., Cohen W. I., Mathis C. A., Price J. C. and Klunk W. E. (2012) Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement. 8, 496501.
  • Hashimoto T., Wakabayashi T., Watanabe A. et al. (2002) CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J. 21, 15241534.
  • Hayashi H., Kimura N., Yamaguchi H. et al. (2004) A seed for Alzheimer amyloid in the brain. J. Neurosci. 24, 48944902.
  • Ikonomovic M. D., Klunk W. E., Abrahamson E. E. et al. (2008) Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131, 16301645.
  • Ikonomovic M. D., Abrahamson E. E., Price J. C. et al. (2012) Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol. 123, 433447.
  • Jack C. R., Jr, Knopman D. S., Jagust W. J., Shaw L. M., Aisen P. S., Weiner M. W., Petersen R. C. and Trojanowski J. Q. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119128.
  • Jack C. R., Jr, Knopman D. S., Jagust W. J. et al. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207216.
  • Jucker M. (2010) The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat. Med. 16, 12101214.
  • Kakuyama H., Soderberg L., Horigome K., Winblad B., Dahlqvist C., Naslund J. and Tjernberg L. O. (2005) CLAC binds to aggregated Abeta and Abeta fragments, and attenuates fibril elongation. Biochemistry 44, 1560215609.
  • Klunk W. E., Engler H., Nordberg A. et al. (2003a) Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin. N. Am. 13, 781789, ix.
  • Klunk W. E., Wang Y., Huang G. F. et al. (2003b) The binding of 2-(4’-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 23, 20862092.
  • Klunk W. E., Lopresti B. J., Ikonomovic M. D. et al. (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 1059810606.
  • Kodali R., Williams A. D., Chemuru S. and Wetzel R. (2010) Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. J. Mol. Biol. 401, 503517.
  • Kowa H., Sakakura T., Matsuura Y., Wakabayashi T., Mann D. M., Duff K., Tsuji S., Hashimoto T. and Iwatsubo T. (2004) Mostly separate distributions of CLAC- versus Abeta40- or thioflavin S-reactivities in senile plaques reveal two distinct subpopulations of beta-amyloid deposits. Am. J. Pathol. 165, 273281.
  • Kulathu Y. and Komander D. (2012) Atypical ubiquitylation – the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 13, 508523.
  • Landt J., D'Abrera J. C., Holland A. J. et al. (2011) Using positron emission tomography and carbon 11-labeled pittsburgh compound b to image brain fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility. Arch. Neurol. 68, 890896.
  • Lee S. J., Liyanage U., Bickel P. E., Xia W., Lansbury P. T., Jr and Kosik K. S. (1998) A detergent-insoluble membrane compartment contains Abeta in vivo. Nat. Med. 4, 730734.
  • Lemere C. A., Grenfell T. J. and Selkoe D. J. (1999) The AMY antigen co-occurs with abeta and follows its deposition in the amyloid plaques of Alzheimer's disease and Down syndrome. Am. J. Pathol. 155, 2937.
  • Liu Q., Wu W. H., Fang C. L. et al. (2011) Mapping ApoE/Abeta binding regions to guide inhibitor discovery. Mol. BioSyst. 7, 16931700.
  • Lu J. X., Qiang W., Yau W. M., Schwieters C. D., Meredith S. C. and Tycko R. (2013) Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154, 12571268.
  • Marutle A., Gillberg P. G., Bergfors A., Yu W., Ni R., Nennesmo I., Voytenko L. and Nordberg A. (2013) 3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar beta-amyloid in Alzheimer brain. J. Neuroinflammation 10, 90.
  • Ni R., Gillberg P. G., Bergfors A., Marutle A. and Nordberg A. (2013) Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain 136, 22172227.
  • O'Nuallain B., Williams A. D., Westermark P. and Wetzel R. (2004) Seeding specificity in amyloid growth induced by heterologous fibrils. J. Biol. Chem. 279, 1749017499.
  • Osada Y., Hashimoto T., Nishimura A., Matsuo Y., Wakabayashi T. and Iwatsubo T. (2005) CLAC binds to amyloid beta peptides through the positively charged amino acid cluster within the collagenous domain 1 and inhibits formation of amyloid fibrils. J. Biol. Chem. 280, 85968605.
  • Oshima N., Morishima Kawashima M., Yamaguchi H., Yoshimura M., Sugihara S., Khan K., Games D., Schenk D. and Ihara Y. (2001) Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain. Am. J. Pathol. 158, 22092218.
  • Paravastu A. K., Leapman R. D., Yau W. M. and Tycko R. (2008) Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc. Natl Acad. Sci. USA 105, 1834918354.
  • Paravastu A. K., Qahwash I., Leapman R. D., Meredith S. C. and Tycko R. (2009) Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc. Natl Acad. Sci. USA 106, 74437448.
  • Petkova A. T., Leapman R. D., Guo Z., Yau W. M., Mattson M. P. and Tycko R. (2005) Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307, 262265.
  • Ramanan V. K., Risacher S. L., Nho K. et al. (2013) APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol. Psychiatry 19, 351357.
  • Roher A. E. and Kuo Y. M. (1999) Isolation of amyloid deposits from brain. Methods Enzymol. 309, 5867.
  • Roher A. E., Lowenson J. D., Clarke S. et al. (1993a) Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 268, 30723083.
  • Roher A. E., Palmer K. C., Yurewicz E. C., Ball M. J. and Greenberg B. D. (1993b) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J. Neurochem. 61, 19161926.
  • Rosen R. F., Ciliax B. J., Wingo T. S., Gearing M., Dooyema J., Lah J. J., Ghiso J. A., LeVine H., 3rd and Walker L. C. (2010) Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol. 119, 221233.
  • Rosen R. F., Walker L. C. and LeVine H., 3rd (2011) PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol. Aging 32, 223234.
  • Snellman A., Lopez-Picon F. R., Rokka J., Salmona M., Forloni G., Scheinin M., Solin O., Rinne J. O. and Haaparanta-Solin M. (2013) Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J. Nucl. Med. 54, 14341441.
  • Soderberg L., Kakuyama H., Moller A., Ito A., Winblad B., Tjernberg L. and Naslund J. (2004) Characterization of the Alzheimer's disease-associated CLAC protein and identification of an Abeta binding site. J. Biol. Chem. 280, 10071015.
  • Soderberg L., Dahlqvist C., Kakuyama H., Thyberg J., Ito A., Winblad B., Naslund J. and Tjernberg L. O. (2005) Collagenous Alzheimer amyloid plaque component assembles amyloid fibrils into protease resistant aggregates. FEBS J. 272, 22312236.
  • Sperling R. A., Aisen P. S., Beckett L. A. et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280292.
  • Svedberg M. M., Hall H., Hellstrom-Lindahl E., Estrada S., Guan Z., Nordberg A. and Langstrom B. (2009) [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int. 54, 347357.
  • Tong Y., Xu Y., Scearce-Levie K., Ptacek L. J. and Fu Y. H. (2010) COL25A1 triggers and promotes Alzheimer's disease-like pathology in vivo. Neurogenetics 11, 4152.
  • Toyama H., Ye D., Ichise M. et al. (2005) PET imaging of brain with the beta-amyloid probe, [(11)C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 32, 593600.
  • Villemagne V. L., Burnham S., Bourgeat P. et al. (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357367.
  • Wisniewski T., Lalowski M., Golabek A., Vogel T. and Frangione B. (1995) Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345, 956958.
  • Yanagisawa K. and Ihara Y. (1998) GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain. Neurobiol. Aging 19, S65S67.
  • Yanagisawa K., Odaka A., Suzuki N. and Ihara Y. (1995) GM1 ganglioside-bound amyloid beta-protein (Abeta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 10621066.
  • Yanagisawa K., McLaurin J., Michikawa M., Chakrabartty A. and Ihara Y. (1997) Amyloid beta-protein (Abeta) associated with lipid molecules: immunoreactivity distinct from that of soluble Abeta. FEBS Lett. 420, 4346.